Haifa's Lexiphon signed a memorandum of understanding with the Chinese city of Changzhou * Pluristem CEO Zami Aberman was named to the list of the 50 most influential people in the world of stem cells * an agreement for gluten biodiesel in Latin America and more
Last week, a memorandum of understanding was signed between the Haifa Lexiphone company headed by Dr. Ike Sagia, the founder and CEO, and the representative of the city, the deputy head of Changzhou's local government, Mr. Fang Guoqiang, in charge of economic development.
Fang is currently visiting Israel at the head of a delegation of senior officials from the city for meetings and agreements with Israeli technology companies. The PTL Group company headed by Zvi Shelgo, chairman of the Israeli Chamber of Commerce in Shanghai, is entrusted with the initiative of the agreement and its actual implementation. Lexiphone has developed a technology that enables simultaneous translation between two speakers, when each of them speaks a different language. The company's translation system is based on real-time access to the computing power of smart servers, and today is able to translate the most common languages - Chinese, French, English, German, Spanish, Russian, Italian, Portuguese and more.
The service provided by the company translates phone calls in real time from one language to another and vice versa, thus allowing people who do not speak a common language to communicate with each other on the phone. The company was founded by Dr. Yitzhak "Ike" Sagi, founder and CEO of the company. "China has become a formidable economic power in recent years and the language barrier is still a difficulty in international business," says Dr. Ike Sagui, CEO of Lexiphone. As part of the agreement, Lexiphone intends to recruit a team of about 10 people, including mainly Chinese linguists as well as service and support personnel.
The company intends to develop a component of the company that adapts it to the Chinese market. Lexiphone, from its main development center in Israel, will guide the team closely from a scientific point of view. Lexiphone intends to raise about 10 million dollars for the purpose of expanding its activities, including in China. According to Zvi Shelgo, CEO of PTL Group, "Changzhou has already demonstrated its capabilities and desire to provide strong local encouragement to Israeli companies - including small and medium-sized companies"
"We intend to continue and expand the cooperation with Israeli technology companies, until the establishment of a complete Chinese-Israeli technology park in Changzhou" said Fang Guoqiang, Deputy Mayor of Changzhou. At an event held at the Gemini Foundation offices in honor of the delegation,
Galten Biodiesel announces strategic cooperation in Latin America
The Geltan Biodiesel company, which works to grow and produce oil from the jatropha plant, announces a strategic collaboration in Latin America. The company signed a document of principles to establish a joint company, in equal parts, with the Mexican infrastructure giant Constructa Cota SA. The purpose of the collaboration is to grow jatropha trees in Mexico in order to produce crude vegetable oil in commercial quantities. Also, the companies will work jointly in projects related to jatropha in Latin America.
Doron Levy, Chairman of the Galtan Board of Directors: "The biodiesel field in which we are active arouses great interest among companies and organizations all over the world. The signing of the document of principles for the establishment of a joint company that will operate in Latin America and the willingness of an old and experienced business entity to invest millions of dollars is proof of the commercial potential inherent in the production and sale of oil from the jatropha plant. We believe that in the coming years we will realize the business plan to increase the yielding jatropha areas of the company".
Pluristem CEO Zami Aberman was named to Forbes' list of the 50 most influential people in the world of stem cells
Ahead of the annual conference for restorative medicine in London, which will be held in May 2013 and will focus on the field of stem cells, the organizers have revealed the list of the 50 most prominent and influential figures in the global stem cell industry. Zami Aberman, CEO of the Israeli company Pluristem, was ranked 19th in the prestigious list, defined by them as "Forbes' 100 most influential people - of the world of stem cells".
The 50 people were chosen by thousands of surveyors from the scientific, medical and professional community dealing with stem cells. Alongside Aberman, the only Israeli on the list, the list includes world-renowned academics, major players in the pharmaceutical market, senior officials in regulatory bodies, and more. The company Terrapinn, which is behind the conference and the survey, is considered one of the most respected and leading companies in the biomedicine industry in the world, and its conferences are a magnet for community leaders. The 50 influential people in the industry were ranked according to significant achievements they reached during their careers, such as a breakthrough discovery, innovative research, providing funding, a lifetime achievement, or being a source of inspiration to others.
The choice of Aberman was justified by the fact that he "joined Pluristem in September 2005 and led a strategic change in the company towards the treatment of vascular diseases. Aberman's vision to use the maternal part of the placenta as a source of cellular healing in combination with Pluristem's XNUMXD multi-cell technology, led the company to develop unique products. Pluristem Therapeutics Ltd. is a biotechnology company that develops cell therapies for a variety of human diseases.
Pluristem's cell products are extracted from human placentas, which are usually discarded as medical waste after birth. Pluristem multiplies these placental cells using a unique and exclusive XNUMXD platform for the company that ensures efficient and controlled mass production of the company's cell products, called PLAcental eXpanded (PLX) cells. The PLX cells work by secreting chemokines, cytokines and medicinal growth factors in response to signals produced by inflammatory and ischemic disorders within the body. The PLX cells are available for use in patients immediately and genetic compatibility between the placenta donor and the patient is not required before the treatment is administered.
One response
Take google translator, chained to it an artificial voice, and we have an interpreter from any language to any language, of reasonable quality. True in about 20% or more, of the cases the translation doesn't hit, but it's good enough. Why reinvent the wheel again.
Google's engine with a human voice interface and internet browsing capability is good enough.